Raptiva Drug Recall
It was reported in an article yesterday, April 8, 2009 that Raptiva (efalizumab), used to treat patients with chronic plaque psoriasis, has been taken off the U.S. market by manufacturers Genetech, Inc.
The company has withdrawn the defective product because of a potential risk of patients developing progressive multifocal leukoencephalopathy (PML), a rare and seriously fatal neurologic disease caused by a virus that affects the central nervous system. Genetech estimates that 46,000 patients worldwide have been treated with Raptiva since its FDA approval in 2003.
Approximately 2,000 patients in the U.S. may be receiving Raptiva for chronic plaque psoriasis. Anyone who is currently taking Raptiva should see their physician immediately to discuss alternative treatment. There is potential for severe psoriasis worsening if a patient abruptly discontinues using Raptiva, which is why patients must talk with their doctor before stopping treatment.
PML is not the only side effect from use of the dangerous drug Raptiva. Since the drug is an agent which suppresses the immune system, many serious viral and bacterial infections have been known to occur.
Examples of the types of infections that can result from use of Raptiva include:
• Encephalitis
• Pneumonia
• Meningitis
• invasive fungal disease
• Sepsis
• other opportunistic infections.
Manufacturers have an obligation to ensure that their products, including pharmaceuticals, are safe and are required to accurately warn of any hazards or side effects that could take place. If you or someone you know has used Raptiva or is presently using the dangerous drug, you need the knowledge, skills and dedication of an experienced Jacksonville Raptiva litigation attorney. At Farah & Farah, we will help you seek justice for the damages done to you by negligent drug manufacturers of Raptiva. Call us at 1-800-533-3555 today for a case evaluation.
